Washington, Sept 27: A researcher at Tel Aviv University’s Sackler School of Medicine has developed what could be a new weight-loss wonder drug, which not only quells the desire to consume fatty foods, but also has fewer side effects.

Dr. Nir Barak developed the drug in conjunction with the drug company Obecure.

The drug, called HistaleanTM, is based on betahistine, an approved drug used for the treatment of vertigo.

Washington, Sept 27 : American researchers have developed a new drug, that when administered along with chemotherapy, shows promise in treating advanced melanoma, delaying the progression of cancer and prolonging the lives of patients.

The new drug, STA-4783, is the first in a new class called oxidative stress inducers.

Washington, Sept 27 : A new research has revealed that patients with both Clostridium difficile infection (C-difficile) and inflammatory bowel disease (IBD) like Crohn’s disease or ulcerative colitis, are four times more likely to die than patients with just IBD or C difficile infection.

Clostridium difficile infection is the main cause of diarrhoea among patients, and in recent years, the numbers of new cases of the infection have been steadily increasing.

Washington: A new study has discovered that too much sleep can double up person’s death risk. The researchers have revealed that sleeping too much can also be harmful, as lack of sleep doubles a person’s death risk from heart disease.

The researchers group from the University of Warwick and University College London presented the findings to the British Sleep Society in Cambridge.